Lupin receives US FDA approval for antidepressant drug

Topics Lupin Pharma


Drug firm Lupin Monday said it has received approvals from the US health regulator for its Clomipramine Hydrochloride capsules, and Potassium Chloride for oral solution.

The company has received approval from the United States Food and Drug Administration (USFDA) to market its generic Clomipramine Hydrochloride capsules USP in the strengths of 25 mg, 50 mg, and 75 mg, Lupin said in a filing to BSE.

The product is a generic version of SpecGx LLC's Anafranil capsules in the same strengths, it added.

The capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD), Lupin said.

As per IQVIA MAT September 2018 data, Anafranil capsules in the same strengths had annual sales of around USD 109.6 million in the US, it added.

In a separate filing, Lupin said it has received approval from the USFDA to market its Potassium Chloride for oral solution USP, 20 mEq.

The company's product is the generic version of Pharma Research Software Solution LLC's Potassium Chloride for oral solution, 20 mEq, it added. The product had annual sales of around USD 105 million in the US, Lupin said.

It "is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient," it added.

Shares of Lupin were trading at Rs 835 per scrip on BSE, down 1.86 per cent from the previous close.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel